Devyser acquires Swedish company Cybergene AB and strengthens its position in the aneuploidy market
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...
In this paper Dr. Dan Hauzenberger, Medical Director of the Section for Transplantation Immunology at Karolinska University Hospital and Chief Medical Officer at Devyser explains that, monitoring for mixed chimerism in patients after HSCT has in several studies been shown to be of
clinical importance. The main purpose of the assay is
to verify engraftment and subsequently monitor for
the presence of MRD and potentially early detection
of possible relapse.
In this paper Dr. Dan Hauzenberger, Medical Director of the Section for Transplantation Immunology at Karolinska University Hospital and Chief Medical Officer at Devyser explains that, monitoring for mixed chimerism in patients after HSCT has in several studies been shown to be of
clinical importance. The main purpose of the assay is
to verify engraftment and subsequently monitor for
the presence of MRD and potentially early detection
of possible relapse.
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...
Read More
Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA...
Read More
Devyser is proud to announce that the company has been awarded a tender by Oslo University Hospital...
Read More
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a new tender in...
Read More